STOCK TITAN

Sinovac Biotech (NASDAQ: SVA) extends US$55.00 special cash dividend instruction deadline

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Sinovac Biotech Ltd. is extending the deadline for shareholders and nominee brokers to submit payment instructions for its previously declared special cash dividend of US$55.00 per common share. The dividend is payable to valid holders of common shares as of the close of business on May 23, 2025.

The original instruction submission deadline of December 31, 2025 has been pushed back to June 30, 2026, giving eligible holders more time to complete the required materials so they can receive the dividend.

Positive

  • None.

Negative

  • None.
Special cash dividend US$55.00 per common share Previously declared dividend amount
Record date for dividend May 23, 2025 Close of business ET for valid holders
Original instruction deadline December 31, 2025 Initial cutoff for submitting payment instructions
Extended instruction deadline June 30, 2026 New cutoff for submitting payment instructions
special cash dividend financial
"previously announced a special cash dividend of US$55.00 per common share"
A special cash dividend is a one-time, extra cash payment a company gives to its shareholders in addition to its regular dividends, like a bonus check sent out when a business has more cash than usual. It matters to investors because it delivers immediate cash value, can signal that the company has strong short-term cash or limited opportunities to reinvest, and typically reduces the company’s cash reserves and may affect the stock price and tax treatment for recipients.
record date financial
"payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
Information Agent financial
"If you have any questions ... please contact the Information Agent D.F. King & Co., Inc."
An information agent is a person, team, or third-party service designated to collect, verify and distribute a company’s important announcements, filings or notices to regulators, shareholders and the public. Think of it as the company’s official mailroom and translator combined—responsible for making sure the right facts get to the right people quickly and accurately; investors watch who serves this role because mistakes or delays can affect compliance, market reaction and trust.
biopharmaceutical financial
"a leading provider of biopharmaceutical products in China"
A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.
prequalified by WHO financial
"3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive"

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2026

 

 

 

Commission File Number: 001-32371

 

 

 

SINOVAC BIOTECH LTD.

 

No. 39 Shangdi Xi Rd, Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒         Form 40-F ☐

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SINOVAC BIOTECH LTD.
     
  By: /s/ Nan Wang
  Name: Nan Wang
  Title: Chief Financial Officer

 

Date: May 21, 2026

 

1

 

 

Exhibit Index

 

Exhibit 99.1   Press Release

 

2

 

Exhibit 99.1

 

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

 

2026-05-21

 

BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend.

 

The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026.

 

Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to undertake to receive the Dividend, please contact the Information Agent:

 

D.F. King & Co., Inc.

28 Liberty Street, 53rd Floor

New York, NY 10005

Attention: Sinovac Biotech Ltd. Special Dividend

Email: sva@dfking.com, with a subject line of Sinovac Biotech Ltd, Special Dividend

 

Contact

 

Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279 9720
Email: ir@sinovac.com

 

About SINOVAC

 

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

 

The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

 

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world’s first inactivated SARS vaccine (Phase I completed), China’s first H5N1 influenza vaccine (Panflu®), the world’s first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

 

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

 

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

 

For more information, please see the Company’s website at www.sinovac.com.

 

FAQ

What did Sinovac Biotech Ltd. (SVA) announce in this 6-K filing?

Sinovac Biotech Ltd. announced an extension of the deadline to submit payment instructions for its previously declared special cash dividend of US$55.00 per common share. This change affects how long eligible shareholders have to complete the required documentation.

How much is Sinovac Biotech Ltd. (SVA)’s special cash dividend per share?

The special cash dividend is US$55.00 per common share. This amount was previously declared and applies to valid holders of Sinovac’s common shares as of the specified record date in May 2025 mentioned in the announcement.

Who is eligible to receive Sinovac (SVA)’s special cash dividend?

The dividend is payable to valid holders of Sinovac’s common shares as of the close of business on May 23, 2025 ET. Eligibility is tied to share ownership on that record date, not to when instructions are later submitted.

What deadline did Sinovac (SVA) extend for its special cash dividend instructions?

Sinovac extended the deadline for submitting payment instruction materials from December 31, 2025 to June 30, 2026. Shareholders and nominee brokers now have additional time to complete and submit forms needed to receive the dividend payment.

Where can Sinovac (SVA) shareholders get help with the special dividend process?

Shareholders can contact the Information Agent D.F. King & Co., Inc. at its New York address or via the dedicated email, and may also reach Sinovac Biotech Ltd.’s investor relations contact, Helen Yang, by telephone or email for process-related questions.

What type of company is Sinovac Biotech Ltd. (SVA)?

Sinovac Biotech Ltd. is a China-based global biopharmaceutical company focused on vaccines and related biological products for human infectious diseases, including influenza, hepatitis, polio, varicella, HFMD, and COVID-19, with several vaccines prequalified by the World Health Organization.

Filing Exhibits & Attachments

1 document